**Title:**

Co-design of patient information leaflets for germline predisposition to cancer: Recommendations for clinical practice from the UK Cancer Genetics Group (UKCGG), Cancer Research UK (CRUK) funded CanGene-CanVar Programme and the Association of Genetic Nurse Counsellors (AGNC)

Kelly Kohut1,2, Beverley Speight3, Julie Young4, Rosalind Way5, Jennifer Wiggins6, Laura Monje-Garcia7,8,9, Diana Eccles2, Claire Foster2, Lesley Turner2, Katie Snape1,10, Helen Hanson1,5, on behalf of the CanGene-CanVar Patient Reference Panel, on behalf of Consensus Meeting Participants

1South West Thames Centre for Genomics, St George’s University Hospitals NHS Foundation Trust, London, UK

2Centre for Psychosocial Research in Cancer (CentRIC+), School of Health Sciences, University of Southampton, Southampton, UK

3East Anglian Medical Genetics Service, Addenbrooke’s Treatment Centre, Addenbrooke’s Hospital, Cambridge, UK

4CanGene-CanVar Patient Reference Panel

5Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK

6Cancer Genetics Unit, The Royal Marsden NHS Foundation Trust, London, UK

7St Mark’s Centre for Familial Intestinal Cancer. The National Bowel Hospital and Academic Institute, London North West University Healthcare NHS Trust, London, UK

8Imperial College, London, UK

9North Thames Genomic Medicine Cancer Alliance, London, UK

10 St George’s University of London, London, UK

**Corresponding author:** Kelly Kohut, k.e.kohut@soton.ac.uk

**Background:** Testing for germline pathogenic variants (GPV) in cancer predisposition genes is increasingly offered as part of routine care for patients with cancer. This is often urgent in oncology clinics due to potential implications on treatment and surgical decisions. This also allows identification of family members who should be offered predictive genetic testing. In the UK, it is common practice for healthcare professionals to provide a patient information leaflet (PIL) at point of care for diagnostic genetic testing in patients with cancer, after results disclosure when a GPV is identified, and for predictive testing of at-risk relatives. Services usually create their own PIL, resulting in duplication of effort and wide variability regarding format, content, signposting and patient input in co-design and evaluation.
**Methods:** Representatives from UK Cancer Genetics Group (UKCGG), Cancer Research UK (CRUK) funded CanGene-CanVar programme and Association of Genetic Nurse Counsellors (AGNC) held a two-day meeting with the aim of making recommendations for clinical practice regarding co-design of PIL for germline cancer susceptibility genetic testing. Lynch syndrome and haematological malignancies were chosen as exemplar conditions.
**Results:** Meeting participants included patient representatives including as Co-Chair, multidisciplinary clinicians and other experts from across the UK. High level consensus for UK recommendations for clinical practice was reached on several aspects of PIL using digital polling, including that PIL should be offered, accessible, co-designed and evaluated with patients.
**Conclusions:** Recommendations from the meeting are likely to be applicable for PIL co-design for a wide range of germline genetic testing scenarios.

**Keywords:** patient information leaflets, cancer genetic testing, mainstreaming genomics, co-design, best practice guidelines

**What is already known on this topic:** co-design is the process of involving patients, clinicians and other expert stakeholders in the process of design. Co-design is recommended for clinical pathways, guidelines and resources to include patients with lived experience as equal partners to improve services. There has been little attention and resource dedicated to co-design of patient information leaflets (PIL) for germline genetic predisposition to cancer, with wide variability in the availability and quality of PIL offered to patients across the UK.

**What this study adds:** this is the first UK meeting dedicated to recommendations for clinical practice for co-design of PIL for cancer genetics.

**How this study might affect research, practice or policy:** services providing genetic testing and follow-up care for patients across the UK have agreed to use nationally developed and updated PIL to provide equity of care and improve patient experience and understanding.

**INTRODUCTION**

Implementation of the National Genomic Test Directory in England (1), along with growing awareness of the relevance of genomics to cancer treatment, surveillance and risk reduction (2-4) has increased the number of people with potential or confirmed germline pathogenic variants (GPV) in cancer predisposition genes. National testing and clinical management guidelines promote access and equity of care for patients. The United Kingdom Cancer Genetics Group (UKCGG) is a Special Interest Group of The British Society for Genetic Medicine (BSGM) with multidisciplinary membership including approximately 350 clinicians and scientists. UKCGG in partnership with other stakeholders have established consensus guidelines on clinical and laboratory pathways for several indications (5-9) (see [UKCGG Consensus Meetings - Cancer Genetics Group](https://www.ukcgg.org/information-education/ukcgg-consensus-meetings/)). Guidelines are hosted on the UKCGG website and updated when evidence or advice changes. Some patient resources on topics such as chemoprevention and *PALB2* GPV are included. However, many of the GPV guidelines do not have associated patient resources, and there is no standard format or template for written information offered to patients.

**Current practice**

There is a network of regional UK genetics services, covering large geographical areas with populations between one to five million. Geneticists and Genetic Counsellors provide education, training and expert advice to non-genetics medical and nursing colleagues to deliver ‘mainstreaming’ of germline genetic testing to eligible patients across primary and secondary care (10-13).

Standard practice is to offer a short patient information leaflet (PIL) at the time of genetic testing or genetic counselling in three scenarios (Figure 1):

1. **Diagnostic genetic/genomic testing:** for patients with cancer. This includes somatic tumour testing to inform treatment and/or germline (constitutional) testing which could have familial implications due to heritable transmission of cancer susceptibility.
2. **Person with a GPV:** post-genetic test results. This informs cancer treatment and management and predicts future cancer risks in the patient tested and their relatives.
3. **Predictive genetic testing:** in at-risk relatives, for a known familial GPV. Testing is offered initially to first-degree relatives and then cascaded to the wider family.

Scenarios 1 & 2 take place in clinical genetics services and mainstream medical settings such as cancer services and haematology (conditions of the blood and bone marrow). GPVs in a cancer susceptibility gene confer increased risks of certain cancers that change over time and are influenced by factors such as gender, prior surgery and treatment, chemoprevention, risk-reducing surgery and modifiable lifestyle factors (14-17). Following genetic test results, patients usually receive appointments across primary and secondary care, at the relevant ages. Scenario 3 is the remit of specialist genetics services. For adult-onset genetic cancer susceptibility, predictive testing is typically delayed until adulthood to preserve decision-making autonomy (18). However, GPV in some genes such as *TP53* confer cancer risks from infancy and therefore testing may be performed via preimplantation genetic testing, prenatally or in childhood.

**PIL challenges and opportunities**

PIL are typically developed in-house by services or taken from the public domain such as charity websites, and only printed in black and white and if short enough, due to limitations in printing and administrative resources. PIL are usually paper documents distributed during clinic appointments or enclosed with patient letters copied to the General Practitioner and other relevant healthcare professionals. PIL and/or letters may also include signposting with links to resources such as websites or PDF leaflets online. However, providers do not typically seek feedback about patients preferred modality or whether they have read paper PIL or accessed websites.

The genes being tested and number of eligible patients has been steadily increasing since the rollout of the NHS Genomic Medicine Service in England (19), with similar trends in Northern Ireland, Scotland and Wales. Demand for testing has outstripped the clinical genetics workforce which has not seen a concordant increase in capacity. Workforce planning is therefore underway (20, 21), but genetics, oncology and haematology clinicians face extreme pressures in clinic, and waiting lists can be long. This leaves little time for robust development of PIL. Importantly, keeping PIL up to date adds extra pressure in a discipline incorporating fast-changing technology and research with evolving knowledge and guidelines. For example, the number of genes on the breast cancer panel test has increased from three to seven. Accurate risk penetrance estimates also necessitate regular review of evidence-based clinical management guidelines.

In addition to time and capacity pressures, there is a lack of standard guidance, frameworks or templates for PIL development in clinical genetics. In contrast, PIL have been legally required to accompany all medicines in the UK since 1999 (22), with best practice guidelines including requirement to consult with target groups of patients (‘users’) to promote accessible information that is easy to understand (23, 24). Variability in training, knowledge and skills for PIL design and user testing has led to inconsistency in the content and format of PIL, with virtually every genetics service provider using their own or none. Although there is a lack of genetics-specific guidance, other frameworks are broadly useful to inform best practice (25-29) and various training resources and toolkits (Table 1).

**Table 1.** List of selected guidelines, frameworks, training resources and toolkits relevant to PIL co-design.

|  |  |  |
| --- | --- | --- |
| **Author/publisher** | **Title** | **URL** |
| Medicines and Healthcare Products Regulatory Agency (MHRA) | Best practice guidance on patient information leaflets (PIL) | <https://assets.publishing.service.gov.uk>  |
| NHS Digital  | Creating better content for users with low literacy | <https://digital.nhs.uk/blog/transformation-blog/2019/creating-better-content-for-users-with-low-health-literacy>  |
| NHS England | Design principles: NHS digital service manual | <https://service-manual.nhs.uk/design-system/design-principles>  |
| NHS England | Accessible Information Standard  | <https://www.england.nhs.uk/about/equality/equality-hub/patient-equalities-programme/equality-frameworks-and-information-standards/accessibleinfo/>  |
| Patient Information Forum (PIF) Tick | Trusted information toolkit for healthcare professionals | <https://piftick.org.uk/healthcare-professionals-information/>  |
| Health Education England | Health literacy ‘how to’ guide | <https://www.hee.nhs.uk/our-work/population-health/training-educational-resources>  |
| Health Education England, Health Dialogues, NHS England Department of Health, Lancashire Care NHS Foundation Trust | Making Every Contact Count (MECC) | <https://www.e-lfh.org.uk/programmes/making-every-contact-count/>  |
| NHS England Department of Health and Social Care | B1762: Guidance on working in partnership with people and communities | <https://www.england.nhs.uk/publication/working-in-partnership-with-people-and-communities-statutory-guidance/> |
| Alexandra Freeman. *Drug and Therapeutics Bulletin*2019; 57**:**119-124. | How to communicate evidence to patients | <http://dx.doi.org/10.1136/dtb.2019.000008> |
| Academy of Medical Royal Colleges | Please, write to me: Writing outpatient clinic letters to patients Guidance | <https://www.aomrc.org.uk/reports-guidance/please-write-to-me-writing-outpatient-clinic-letters-to-patients-guidance/> |

**Co-design with patients and other experts**

Patients with lived experience of genetic testing or a genetic condition are experts in their own care. They should be asked to contribute from the conception stages of research and clinical pathways and will make a thoughtful and valued impact to co-design. Although they may develop into ‘experts’ with experience on patient panels and committees, they continue to represent the wider community and advocate for increased equity, diversion and inclusion of views (30).

**Aims**

A two-day meeting was arranged with the following aims:

1. Agree UK recommendations for clinical practice for the PIL regarding genetic cancer susceptibility testing and management in terms of content and format.
2. Take a co-design approach with patients and other experts to agree recommendations for PIL that can be adopted for specific conditions, starting with Lynch syndrome and germline genetic susceptibility to haematologic cancer, followed by GPV in other cancer susceptibility genes, and GPV in non-cancer related genes (common and rare genetic conditions).
3. Provide consistency across the UK of high-quality information given to patients accessing genetic testing and follow-up care for a GPV in a cancer susceptibility gene.
4. Minimise duplication of effort with every specialist clinical genetics or mainstream service creating their own PIL with limited time and resources to keep these updated. Accomplish this through formation of a national collaboration and working groups.
5. Create a list of trusted, up-to-date patient resources for signposting, stored centrally online via a trusted provider (for example, UKCGG) with links on other relevant websites such as GeNotes, the Genomics Education Programme and various professional resources, patient groups and charities.

**METHODS**

**Pre-meeting planning**

The lead author (KK) submitted a proposal to seek UK consensus on recommendations for clinical practice for co-design of PIL for cancer susceptibility genetic testing and management. This was ratified at the UKCGG Executive Council Meeting on 11/10/2022. Online meetings were scheduled across two mornings. An organising committee was assembled, with all members invited to be co-chairs and named authors. The committee included representatives from clinical genetics (KK/HH/BS/KS/JW), specialist mainstream services providing genetic testing (LMG), UKCGG Council (HH/BS/KS), a patient representative from the CRUK-funded CanGene-CanVar programme (JY) and administrative/management support from the Institute of Cancer Research (RW). The Association of Genetic Nurse Counsellors (AGNC) Chair was also engaged, agreed to co-badge the meetings and delegated a Committee Member to participate.

Lynch Syndrome was used as an exemplar condition for the first meeting and germline predisposition to haematologic malignancies for the second. These were chosen to provide specific content for examples of PIL content and format. Increased testing for Lynch is a current focus of NHS England, with a National Transformation Project (31-33). Germline predisposition to haematological cancer was considered during a recent UKCGG meeting resulting in publication of consensus best practice guidelines (6). Selection of these conditions also allowed for purposive sampling of relevant stakeholders to invite, including patients with lived experience, charities, peer support organisations, medical and academic specialists. KK invited the UK Lead Genetic Counsellor Group and the Lead Cancer Consultant Geneticist Group. All regional and specialist genetics services across the UK were asked to delegate at least one clinician for each meeting.

Registration using the online video conferencing platform <https://zoom.us> (‘zoom’) included expressions of interest to attend one or both meetings. Spaces were unlimited but allocated to promote representation from across the UK and include experts across the spectrum of clinical, research, policy and charity/patient support pathways. There were 10 funded patient representative places each day, with reimbursement in line with [NIHR guidelines](https://www.nihr.ac.uk/documents/payment-guidance-for-researchers-and-professionals/27392).

Relevant background reading materials and pre-meeting surveys (Supplementary File 1) were sent to participants. Survey questions assessed current practice regarding genetic and genomic testing in specialist clinical genetics and mainstream settings, and use of PIL. Participants were asked to add PIL created by their services, or to which they signposted patients, to a shared Google drive folder.

**Meeting content**

Following short presentations about background, best practice guidelines and existing patient information resources (see Agenda, Supplementary File 2), polls using the online platform <https://community.slido.com>(‘Slido’)presented consensus statements for voting regarding recommendations for clinical practice for PIL content and design. UK participants were eligible to vote. Other international experts were invited to participate but did not vote. Consensus was achieved with a threshold of 80% selecting ‘agree/strongly agree’, in accordance with the UKCGG Consensus Meetings Standard Operating Procedure (version 1, 02/12/2022, https://ukcgg.org). If consensus was not reached, the poll question could be revised in real time, but if not reached after a second vote, it was agreed that future work on this question would be required. Voting needed to be completed by at least 80% of UK participants before poll questions were closed.

Discussion and comments were encouraged to capture rich qualitative data to supplement quantitative poll data. The chat function in zoom was used, and participants could turn on their microphone and camera if they wished. The chat text was saved for descriptive analysis. The transcript was reviewed and analysed by the organising committee to identify important themes not captured in the short consensus statements displayed in the Slido polls.

**RESULTS**

**Pre-meeting surveys**Pre-meeting surveys to scope the origin and current use of PIL and other resources received low response rates: n=16/104 (15%) for the first meeting (Lynch) and n=23/147(16%) for the second (Haematology).

Results from the Lynch pre-meeting survey showed that 11/16 responders provided a PIL. Nine out of 11 were locally written and curated PIL and 2/9 were created with patient involvement. Fifteen out of 16 responders signposted patients to charities or support organisations, the vast majority to Lynch Syndrome UK. In response to a question about what additional resources would be helpful, comments were made about gene-specific risks/management, as well as PIL for different stages of the genetic testing pathway.

Four out of 23 responders to the haematology pre-meeting survey indicated they provided a PIL, and these were locally written/curated. Nine out of 23 responders signposted patients to charities or support organisations. Named charities included MDS UK Patient Support Group, Leukaemia Care, Macmillan Cancer Support and Blood Cancer UK. Comments showed a demand for PIL to address somatic versus germline genetic variants, familial implications, predictive testing and gene-specific risks/management.

**Collation of PIL in current use**
PIL in current use were added to a shared Google drive by 7/23 regional genetics services in the UK and three specialist genetics service or patient charities. These varied in length, content and format. There was a lack of patient co-design, or at least notation of this on the PIL. Outreach to services that were non-responders will be undertaken by working groups overseen by the AGNC, in preparation for future work to develop condition specific PIL.

Meeting participants
Over 100 invitations were sent inviting patients and professionals to attend one or both meetings, share with their team and/or suggest relevant stakeholders. Interest in the meetings was universal, but availability to attend and complete the pre-meeting surveys was limited due to time pressures, clinics and other commitments. Three patients and 17 professionals attended both meetings, but only voted once (on Day 2). All other participants attended one meeting and voted once in the polls. There were 48/61 engaged with polls in the first meeting and 43/57 in the second.

Digital polling and consensus statement agreement
Recommendations for clinical practice are presented in Table 2. Detailed poll results are presented in Supplementary Table. Questions were grouped into seven sections/subheadings to address the following topics: diagnostic genetic/genomic testing, patients with a GPV in a cancer susceptibility gene, predictive genetic testing, PIL format, PIL content, risk communication and communicating uncertainty.

**Table 2.** Recommendations for clinical practice from the UK Cancer Genetics Group (UKCGG), Cancer Research UK (CRUK) funded CanGene-CanVar Programme and the Association of Genetic Nurse Counsellors (AGNC) on co-design of patient information leaflets (PIL) for germline predisposition to cancer.
**Note for Table 2:** see Supplementary Table for more details about discussion and recommendations from meeting participants.

|  |  |  |
| --- | --- | --- |
| **PIL indication/topic:** | **Recommendations for clinical practiceIt should be best practice for PIL:** | **Suggestions from meeting discussion:**  |
| **Diagnostic genetic testing** | to be offered to people with cancer or a pre-malignant condition being offered genetic/genomic testing  | -need less detail pre-results |
| **Pathogenic gene variant**  | to be offered to people who have a pathogenic variant in a cancer susceptibility gene  | -mostly generic PIL + personalised letter  |
| **Predictive genetic testing** | to be offered to people being offered predictive testing (in addition to a copy of their clinic letter) | - at-risk relatives should be referred for genetic counselling  |
| **PIL format** | to contain subheadings to make finding information easier. | -should stand out-e.g. bold |
|  | subheadings to be presented in the form of questions |  |
|  | to include pictures to help explain key concepts |  |
| **PIL content** | to mention psychological aspects/feelings related to having genetic testing  |  |
|  | to include links to relevant charities | -check trusted  |
|  | to include links to relevant patient peer support groups |  |
|  | to include information about family planning/reproductive options, where relevant | -check phrasing with patients |
|  | about genetic testing to present all the choices, including to do nothing/not have genetic testing |  |
|  | about genetic testing to mention rules about genetic testing and insurance | -see [ABI](https://www.abi.org.uk/data-and-resources/tools-and-resources/genetics/code-on-genetic-testing-and-insurance/) Code |
|  | about genetic testing to mention what might happen after results |  |
|  | for people with a pathogenic gene variant to mention that more personalised information can be provided during an appointment with genetics or other specialists | -precise estimates might not be available  |
|  | to be checked using a readability tool such as SMOG with the aim of achieving a reading level of 9-11 years. Medical terms may be temporarily removed, then added back into the PIL, making sure they are clearly explained. | -aim for national reading age  |
|  | to include simple explanations for any medical jargon or complex language |  |
|  | to include the term pathogenic gene variant to match the term on genetic test reports | -other descriptions can be included |
|  | to be translated into the patient’s first language, if resources are available |  |
|  | to be reviewed by patients with lived experience of the condition | -cost for this |
|  | to consider language and aim to be as inclusive as possible for all patients, including those with protected characteristics | -co-design with these patients  |
|  | to have a date issued and date due for review | -secure funding  |
| **Risk communication** | to include information about the chances of getting cancer/pre-malignant conditions, where relevant |  |
|  | to present chances for people to get cancer/premalignant conditions with numbers as well as words (for example, showing % or a x/10 or x/100 people, not just saying ‘high’ or ‘low’ chance) |  |
|  | to include visual presentation of the chances of getting cancer/premalignant conditions, for example icon arrays (repeated shapes showing people affected in a different colour), graphs, bar charts. | -icon arrays preferred  |
|  | to include contact details for relevant health care professionals/services (for example, genetics, oncology, haematology) |  |
| **Communicating uncertainty** | to explain uncertainty, including where it comes from (such as lack of scientific knowledge, not enough families to study) and how this might make people feel | -area for further research |

Consensus was reached on all statements when voting across both days was considered. The same statements were presented at both meetings. There were two statements where consensus was not reached on Day 2 only, one regarding including links to peer support groups (Agree/Strongly agree: Day 1= 87%; Day 2=79% + 16% neutral/no opinion, Supplementary Table, Section 5) and one regarding phrasing subheadings in the form of questions (Agree/Strongly agree: Day 1= 84%; Day 2=65% + 26% neutral/no opinion, Supplementary Table, Section 4).

There was some minor revision of the statements agreed in real time on Day 2, shown with tracked changes (Supplementary Table). There was little opportunity to explain complicated concepts due to the character limit for Slido. Rewording was based on in-meeting feedback and aimed at increasing statement clarity.

**Descriptive summary of discussions**

A descriptive summary is presented below, under poll topic heading.

1. Diagnostic genetic/genomic testing

Most genetic testing discussions occurred within clinical genetics services. This may not be representative of the proportion of tests undertaken within clinical genetics versus a mainstream setting, but rather could reflect the fact that most meeting participants were from clinical genetics. High level consensus was reached regarding the offer of a PIL at the time of diagnostic genetic testing. Chat analysis showed that participants did not feel this needed to be extensively detailed, especially since some genetic tests are broad and most patients do not have a GPV identified. A shorter PIL was suggested, which could be replaced by a longer, more specific and detailed PIL if a GPV was identified.

1. Patients with a GPV (mutation)

Most genetic test results were delivered by specialist clinical genetics services, with a minority by oncology. Again, this may be representative of participant specialty, rather than an overall practice in the UK. High level consensus was reached regarding the offer of a gene specific PIL at this stage in the pathway of care. Chat comments suggested it was acceptable for the PIL to be comprised of mostly generic information if it accompanied a personalised clinical letter.

1. Predictive genetic testing

Most discussions took place within specialist clinical genetics services. High level consensus was reached regarding the offer of genetic counselling and a PIL at the time of predictive testing.

1. PIL format

Most people felt that up to two sides of A4 paper should be the maximum length. Chat comments showed that longer PIL, such as The Royal Marsden Beginner’s Guide to Lynch Syndrome could also be useful, but this is rarely printed due to length. High level consensus was reached on the need to include sections with subheadings. There was verbal and chat discussion about whether PIL subheadings should be presented in the form of questions. Participants felt this could make the PIL appear more personal but could also reduce relevance for some patients, dependent on the topic.

1. PIL content

Many consensus statements on Day 2 were revised live, based on participant feedback. Several referred to inclusion of certain information, such as reproductive risks. Discussion suggested some sections would not be relevant to many patients. Changes are shown in Supplementary Table, mostly adding ‘where relevant’ to reflect that it would only be appropriate in specific situations, for example involving a patient of reproductive age. For GPV in many cancer susceptibility genes, there is insufficient evidence to provide personalised risk estimates. It was felt that healthcare professionals should not over-emphasise the possibility of this where data is scarce and there are no management guidelines. Preferences for terminology to describe results from cancer susceptibility gene testing ranked ‘mutation’ below gene alteration, gene change and pathogenic variant, which fits with a general trend away from using mutation in clinical practice due to its potential negative connotations.

1. Risk communication

Polling questions revealed the importance of showing visual presentations of the chance of getting cancer in the future, rather than only describing risk in words. This can be achieved with numbers, pictures and graphics. Discussion highlighted the icon arrays in the NICE patient decision aid for Lynch syndrome: S*hould I take aspirin to reduce my chance of getting bowel cancer?* (34) as particularly helpful.

1. Communicating uncertainty

Consensus statements showed the importance of conveying the origin of uncertainty and ranked showing the range of known risks above other options. In situations where this is not possible, the chat suggested it would be acceptable to convey the amount of uncertainty in words, for example ‘some uncertainty’, or ‘a lot of uncertainty’.

**DISCUSSION**

This was the first UK meeting dedicated to recommendations for clinical practice for PIL for testing and management of genetic cancer susceptibility. There was active participation and support from a multidisciplinary group of healthcare and academic professionals from across the UK together with patients, charities and peer support groups. Consensus was reached on all statements when poll results across both days were considered. Live discussion amongst presenters and participants resulted in some minor revisions to some statements on Day 2. Overall, results indicated shared enthusiasm to collaborate and make best use of limited resources to improve the quality, usefulness and consistency of PIL offered to patients. Pre-meeting survey response rate was low, reflecting time pressure from attendees. The limited responses revealed variability in PIL use, format and content in the context of testing and management of genetic cancer susceptibility. There was limited evidence of patient co-design and many PIL contained complex terminology resulting in a high reading level, with limited use of visual presentation of cancer risks and communication about uncertainty. This was not surprising, given the stretched resources in healthcare services making co-development of robust PIL that meet the NHS Accessible Information Standard (26) and contain up to date, evidence-based information a challenge, particularly for genetics which is a rapidly developing specialty with an ever-increasing relevance to various points of care for patients in virtually all areas of medicine. Variability across services and geographies has made delivery of best practice guidelines challenging (9) and predictably patient experience with PIL has also been mixed, from not receiving PIL at all, to PIL ranging from low to excellent quality and usefulness. Factors including ease of understanding, experience and emotions can also affect how meaningful PIL are for patients (35, 36). This is often unexplored when there is only one version available and no evaluation by patients who might benefit the most from more simple PIL (37), although ‘easy read’ versions that rely mostly on pictures are starting to be developed as options (for examples, see NHS England guide to whole genome sequencing, The Eve Appeal Lynch Syndrome Guide, Beyond Words colonoscopy PIL).

PIL can be improved and made easier to read by using validated readability checker tools such as Flesch-Kincaid (FK), Simple Measure of Gobbledygook (SMOG), Gunning fog index (GFI), Fry, FORCAST and Flesch Reading Ease (FRE) (38), aiming for the national average reading age of 9-11 years. However, better satisfaction have been achieved by involving patients in co-design and evaluating impact (39, 40). Gold standard PIL would be tailored to individuals due to the highly personal nature of health decisions, for example by using computer software (41), although this would require significant research and resource to implement and was recognised as beyond the scope of our recommendations at the current time. National collaboration is an efficient way of pooling limited resources to co-design good quality, useful PIL rather than have many different services either duplicating efforts to produce similar resources, or not securing the time and resource to create and use PIL at all.

Key recommendations for clinical practice from patients and stakeholders contributing to polling and discussions (Table 2) are summarised as:

1.Patients should be offered a PIL, alongside their personalised clinic letter, during the genetic testing process (diagnostic and predictive)

2. PIL should be as inclusive as possible, with attention to readability, separate sections and inclusion of visuals (such as using numbers as well as simple words, pictures, icon arrays)

3. PIL should include date of creation and next review and signpost to relevant charities/support organisations/healthcare services

4. Patients with lived experience of the condition should be invited to co-design and review PIL

**Strengths and limitations**

A major strength of these meetings was inclusion of patients with lived experience of cancer, haematologic conditions and/or genetic testing and representation from patient groups and charities. The virtual meeting format removed cost and time restrictions associated with in-person meetings and therefore encouraged UK-wide representation from clinical genetics services and other specialties including oncology and haematology in addition to expert stakeholders. The group was multidisciplinary which encouraged lively discussion with varied perspectives, views and recommendations based on personal experience, local infrastructure and pathways.

Partnership between UKCGG, CanGene-CanVar and AGNC along with specific cancer and genetic patient groups and charities allowed organisations with shared goals to pool resources including finance, staff and time to maximise efficiency and output.

Funding was only available for 10 patients per day; this included remuneration for time spent preparing and attending the meetings. Although not all claimed this offer of reimbursement, funding must be available at the planning stage, which therefore limited the number of patients invited. It would have been beneficial to have more patients to increase the number and diversity of viewpoints. This will be the focus of future funding requests for follow-on work co-designing condition-specific leaflets.

Only two conditions, Lynch and haematological malignancies were used to consider specific PIL content. It was challenging to fully consider the complexities of these two conditions given the various genes and corresponding guidelines. Further, more focussed working groups will be convened to fully explore the views and preferences for these patient groups before moving onto other conditions, applying what has been learned to the generic PIL template design. Additional resource is required and will be the subject of future funding applications.

**CONCLUSIONS**

Regarding the aims of the meetings:

1. UK consensus was achieved on recommendations for clinical practice for PIL content and format regarding genetic cancer susceptibility testing and management.
2. A co-design approach was taken with patients and other expert stakeholders.
3. The recommendations will promote consistency across the UK of high-quality information given to patients.
4. Duplication of effort has been reduced through formation of a national collaboration and working groups.
5. Work has been initiated to create a list of trusted, up-to-date external resources stored centrally online.

This work provides a unique contribution to the literature, reporting the first UK meeting on co-design of PIL for cancer genetics. National collaboration was effective to maximise resources with the shared aim of improving patient care and resources.

**Future work**

A collaboration has been initiated with the newly formed AGNC Working Group on PIL to maximise output by adapting the UKCGG PIL consensus template for other genetic conditions, starting with cancer susceptibility genes and then considering non-cancer related genetic conditions.

Charities and patient groups relevant to the condition-specific leaflets will be invited to review the content and put the PIL through their internal processes to consider co-badging. This could increase trust from some patients who have confidence in information provided by patient-led organisations rather than government, medical or academic institutions.

PIL will be hosted on the [UKCGG website](https://www.ukcgg.org/information-education/patient-resources/), freely accessible alongside current clinical guidelines for GPV in cancer susceptibility genes. A publication date and review date will be noted in the PIL footer. Future funding will be sought to ensure dedicated time to update the PIL when needed, with input from a diverse group including patients, charities and other expert stakeholders.

**AUTHOR CONTRIBUTIONS**

All named authors were part of the organising committee and/or contributed significantly to the planning, delivery or manuscript preparation. All named authors have reviewed the manuscript and approved this for submission. Kelly Kohut- conceptualisation, organisation and chairing of meeting, oversight of process, drafting manuscript and editing with co-author comments. Beverley Speight, Julie Young, Jennifer Wiggins, Laura Monje-Garcia, Katie Snape, Helen Hanson - organisation and co-chairing meeting, review of manuscript. Diana Eccles, Claire Foster – organisation, manuscript preparation and review. Rosalind Way- organisation of meeting, management of delegate invitation and attendance, output from digital polls, manuscript preparation and review. CanGene-CanVar Patient Reference Panel Members Caroline Dale, Sue Duncombe, Rochelle Gold, Sonia Patton, Warren Rook, Richard Stevens, Lesley Turner, Frankie Vale, Helen White, Ivan Woodward, Steve Worrall, Julie Young- reviewed and approved the manuscript. Meeting attendees and presenters Lily Barnett, Marion Bartlett, Julian Barwell, Dany Bell, Bhavana Bhinder, Matilda Bradford, Lydia Brain, Victoria Campbell, Andrew Clark, Emily Clarke, Gemma Corbett, Dharmisha Chauhan, Ruth Cleaver, Beth Coad, Alice Coulson, Lorraine Cowley, Howard Crosskey, Vicky Cuthill, Ajay Dave, Rosemarie Davidson, Chris Dugmore, Jacqueline Dunlop, Diana Eccles, Courtney Elliot, Clair Engelbrecht, Malee Fernando, Claire Foster, Alexandra Freeman, Sarah Gibson, Rochelle Gold, Joana Gomes, Jennifer Gorrie, Andrew Green, Dorothy Halliday, Helen Hanson, Diane Hiscock, Deborah Holliday, Esther Horton, Wendy Ingram, Margaret James, Makaela Jacobs-Pearson, Charlotte Jaggard, Rosalyn Jewell, Siobhan John, Annie Johnes, Lynne Jones, Bhavana Kharay, Kelly Kohut, Claire Kulke, Joanna Large, Celine Lewis, Anne Lowry, Sianan MacParland, Martin Mansell, Charlotte Martin, Richard Martin, Claire McKeeve, Terri McVeigh, Tracie Miles, Kevin Monahan, Laura Monje-Garcia, Alex Murray, Hannah Musgrave, Grace Norman, Emma Oborne, Kai Ren Ong, Nicola Onyeador, Phil Ostrowski, Debbie Pitfield, Manoj Raghavan, Gillian Rea, Alistair Reid, Sarah Salter, Gillian Scott, Collette Scrace, Claire Searle, Monisha Shanmugasundaram, Stan Shepherd, Katherine Smith, Lelsey Snadden, Katie Snape, Tristan Snowsill, Beverley Speight, David Springham, Barbara Stayner, Tilly Tilbrook, Bethany Torr, Olga Tsoulaki, Lesley Turner, Stefania Vicari, Hayley Walsh, Rosalind Way, Sarah Westbury, Helen White, Jennifer Wiggins, Lisa Wilde, Emma Woodward, Julie Young -reviewed and approved the manuscript.

COLLABORATOR STATEMENT:

The members of the CanGene-CanVar patient reference panel are acknowledged for their review and approval of the manuscript. All names are listed below, including those who made additional contributions and are included as named authors and/or meeting attendees. The meeting attendees and presenters are acknowledged for their contributions to the meeting including responding to email invitations, sharing with team members and/or other relevant stakeholders and/or attending and voting in one or both meetings along with review and approval of the manuscript. All meeting attendees/presenters are listed below.

**CanGene-CanVar Patient Reference Panel Members**Caroline Dale, Sue Duncombe, Rochelle Gold, Sonia Patton, Warren Rook, Richard Stevens, Lesley Turner, Frankie Vale, Helen White, Ivan Woodward, Steve Worrall, Julie Young

**Meeting Attendees and Presenters**

Lily Barnett, Marion Bartlett, Julian Barwell, Dany Bell, Bhavana Bhinder, Matilda Bradford, Lydia Brain, Victoria Campbell, Andrew Clark, Emily Clarke, Gemma Corbett, Dharmisha Chauhan, Ruth Cleaver, Beth Coad, Alice Coulson, Lorraine Cowley, Howard Crosskey, Vicky Cuthill, Ajay Dave, Rosemarie Davidson, Chris Dugmore, Jacqueline Dunlop, Diana Eccles, Courtney Elliot, Clair Engelbrecht, Malee Fernando, Claire Foster, Alexandra Freeman, Sarah Gibson, Rochelle Gold, Joana Gomes, Jennifer Gorrie, Andrew Green, Dorothy Halliday, Helen Hanson, Diane Hiscock, Deborah Holliday, Esther Horton, Wendy Ingram, Margaret James, Makaela Jacobs-Pearson, Charlotte Jaggard, Rosalyn Jewell, Siobhan John, Annie Johnes, Lynne Jones, Bhavana Kharay, Kelly Kohut, Claire Kulke, Joanna Large, Celine Lewis, Anne Lowry, Sianan MacParland, Martin Mansell, Charlotte Martin, Richard Martin, Claire McKeeve, Terri McVeigh, Tracie Miles, Kevin Monahan, Laura Monje-Garcia, Alex Murray, Hannah Musgrave, Grace Norman, Emma Oborne, Kai Ren Ong, Nicola Onyeador, Phil Ostrowski, Debbie Pitfield, Manoj Raghavan, Gillian Rea, Alistair Reid, Sarah Salter, Gillian Scott, Collette Scrace, Claire Searle, Monisha Shanmugasundaram, Stan Shepherd, Katherine Smith, Lelsey Snadden, Katie Snape, Tristan Snowsill, Beverley Speight, David Springham, Barbara Stayner, Tilly Tilbrook, Bethany Torr, Olga Tsoulaki, Lesley Turner, Stefania Vicari, Hayley Walsh, Rosalind Way, Sarah Westbury, Helen White, Jennifer Wiggins, Lisa Wilde, Emma Woodward, Julie Young.

**FUNDING STATEMENT**

Helen Hanson, Kelly Kohut, Katie Snape, Bethany Torr and Rosalind Way are supported by funding from Cancer Research UK Catalyst Award CanGene-CanVar [C61296/A27223]. Patient reimbursement expenses were supported by the UK Cancer Genetics Group.

**CONFLICT OF INTEREST STATEMENT**

No conflicting/competing interests declared.

**ETHICS APPROVAL**

Not required

**ORCHID**

Kelly Kohut <https://orcid.org/0000-0002-9852-2872>

Beverley Speight<https://orcid.org/0000-0001-5170-0929>

Helen Hanson <https://orcid.org/0000-0002-3303-8713>

**Figures legend:**

**Figure 1.** Common practice in the UK is for healthcare professionals to provide a patient information leaflet (PIL) at the point at point of care for diagnostic germline testing, after results disclosure when a germline pathogenic variant is identified, and for predictive genetic testing

# Supplementary File 1. Pre-meeting surveys

# Supplementary File 2. Agenda

# Tables legend:

**Table 1.** List of selected guidelines, frameworks, training resources and toolkits relevant to PIL co-design.

**Table 2.** Recommendations for clinical practice from the UK Cancer Genetics Group (UKCGG), Cancer Research UK (CRUK) funded CanGene-CanVar Programme and the Association of Genetic Nurse Counsellors (AGNC) on co-design of patient information leaflets (PIL) for germline predisposition to cancer.

**Note for Table 2:** see Supplementary Table for more details about discussion and recommendations from meeting participants.

**Supplementary Table. Questions presented to participants using the digital polling platform** <https://community.slido.com> **(‘Slido’).** Instructions for consensus statement questions were ‘Please state your level of agreement with the following statement’. Choices were strongly disagree, disagree, neutral/no opinion, agree, strongly agree, I don’t know. Agree and strongly agree were added together to confirm if the threshold of 80% agreement for consensus was reached. Instructions for other voting or rating questions are noted in the tables.
Rewording of some questions was performed in real time on Day 2, based on feedback from the digital chat and verbal discussions. This is indicated by ~~strikethrough~~ of the original wording and new wording presented in **bold**.

**REFERENCES**

1. Barwell J, Snape K, Wedderburn S. The new genomic medicine service and implications for patients Clin Med (Lond). 2019;19(4):273-7.

2. Rahman B, Lamb A, Protheroe A, et al. Genomic sequencing in oncology: Considerations for integration in routine cancer care. European Journal of Cancer Care. 2022;31(3):e13584.

3. Peter M, Hammond J, Sanderson SC, et al. Participant experiences of genome sequencing for rare diseases in the 100,000 Genomes Project: a mixed methods study. European Journal of Human Genetics. 2022;30(5):604-10.

4. Group HGS. Building on our inheritance: Genomic technology in healthcare. 2012.

5. Hanson H, Brady AF, Crawford G, et al. UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants. J Med Genet. 2020;58(2):135-9.

6. Speight B, Hanson H, Turnbull C, et al. Germline predisposition to haematological malignancies: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group. Br J Haematol. 2023.

7. Monahan KJ, Bradshaw N, Dolwani S, et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut. 2020;69(3):411-44.

8. Clark A, Thomas S, Hamblin A, et al. Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT). Br J Haematol. 2023.

9. Hanson H, Kulkarni A, Loong L, et al. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2. J Med Genet. 2022.

10. Confederation N, editor Our inheritance, our future: realising the potential of genetics in the NHS (DOH White Paper)2003.

11. Rahman N. Mainstreaming genetic testing of cancer predisposition genes. Clinical medicine (London, England). 2014;14(4):436-9.

12. Rumford M, Lythgoe M, McNeish I, et al. Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management. Sci Rep. 2020;10(1):3390.

13. Hallowell N, Wright S, Stirling D, et al. Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care. Fam Cancer. 2019;18(3):293-301.

14. Seppälä TT, Burkhart RA, Katona BW. Hereditary colorectal, gastric, and pancreatic cancer: comprehensive review. BJS Open. 2023;7(3).

15. Dominguez-Valentin M, Sampson JR, Seppälä TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med. 2020;22(1):15-25.

16. Dorling L, Carvalho S, Allen J, et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. 2021;384(5):428-39.

17. Fitzgerald RC, Antoniou AC, Fruk L, et al. The future of early cancer detection. Nat Med. 2022;28(4):666-77.

18. Royal College of Physicians British Society for Genomic Medicine. Consent and confidentiality in genomic medicine: Guidance on the use of genetic and genomic information in the clinic. 3rd edition. ed. London: Report of the Joint Committee on Genomics in Medicine. ; 2019.

19. England NHS. NHS Genomic Medicine Service 2021 [Available from: <https://www.england.nhs.uk/genomics/nhs-genomic-med-service/>.

20. Topol E. The Topol Review: Preparing the healthcare workforce to deliver the digital future. 2019.

21. Committee HoCSaT. Genomics and genome editing in the NHS. House of Commons; 2018.

22. Agency MaHpR. Best practice guidance on patient information leaflets. Department of Health and Social Care; 2020.

23. Medicines MaHpRACoSo. Always Read the Leaflet: Getting the best information with every medicine. 2005.

24. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherance. National Institute of Health and Care Excellence; 2009.

25. Health and Social Care Act Section 250, (2012).

26. England N. The Information Standard for Health and Care Information Production Quality Statements. NHS England.

27. England N. Working in partnership with people and communities: statutory guidance. In: Care DoHS, editor. 2022.

28. Freeman ALJ. How to communicate evidence to patients. Drug and Therapeutics Bulletin. 2019;57(8):119.

29. Recchia G, Chiappi A, Chandratillake G, et al. Creating genetic reports that are understood by nonspecialists:a case study. Genetics in Medicine. 2020;22(2):353-61.

30. Hastings Ward J, Middleton R, McCormick D, White H, Kherroubi Garcia I, Simmonds S, et al. Research participants: critical friends, agents for change. European Journal of Human Genetics. 2022;30(12):1309-13.

31. England NHS. Implementing Lynch syndrome testing and surveillance pathways: A handbook to support local systems. 2017.

32. Excellence NIfHaC. [DG27] Molecular testing strategies for Lynch syndrome in people with colorectal cancer. 2017.

33. Excellence NIfHaC. [DG42] Testing strategies for Lynch syndrome in people with endometrial cancer. 2020.

34. Excellence NIfHaC. Lynch syndrome: should I take aspirin to reduce my chance of getting bowel cancer? Patient decision aid. 2020.

35. Medina-Córdoba M, Cadavid S, Pérez-Acosta AM, et al. Factors that Facilitate and Hinder the Comprehension of Patient Information Leaflets (PILs): A Brief Scoping Review. Front Pharmacol. 2021;12:740334.

36. Herber OR, Gies V, Schwappach D, et al. Patient information leaflets: informing or frightening? A focus group study exploring patients' emotional reactions and subsequent behavior towards package leaflets of commonly prescribed medications in family practices. BMC Fam Pract. 2014;15:163.

37. Gillian R, Joanne P, John W, et al. A mismatch between population health literacy and the complexity of health information: an observational study. British Journal of General Practice. 2015;65(635):e379.

38. Hunt WTN, Sofela J, Mohd Mustapa MF. Readability assessment of the British Association of Dermatologists' patient information leaflets. Clin Exp Dermatol. 2022;47(4):684-91.

39. Bishop JL, Jones M, Farquharson J, et al. Patient satisfaction with a consumer codesigned lower limb cellulitis leaflet. Aust Health Rev. 2022;46(1):115-20.

40. Tong V, Raynor DK, Aslani P. Design and comprehensibility of over-the-counter product labels and leaflets: a narrative review. Int J Clin Pharm. 2014;36(5):865-72.

41. Young A, Tordoff J, Smith A. 'What do patients want?' Tailoring medicines information to meet patients' needs. Res Social Adm Pharm. 2017;13(6):1186-90.